CellBion Co., Ltd. (308430.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩11,320 (-5.43%) as of
Key statistics
- Market cap
- 146.09B
- Dividend yield
- 0.00%
- 52-week range
- 9,930.00 – 42,200.00
- Beta
- -0.34
- Revenue (TTM)
- 2.15B
- Profit margin
- 361.16%
- Volume
- 25.74k
About CellBion Co., Ltd.
CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage. It is involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications. CellBion Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.